Investigating dapagliflozin's effects on heart function in chronic kidney disease patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the impact of dapagliflozin on echocardiographic measures of cardiac structure and function in adults with chronic kidney disease (CKD). It is a 6-month, randomized, double-blind, placebo-controlled study involving approximately 222 participants who will receive either 10 mg of dapagliflozin or a placebo. Participants will undergo various assessments, including echocardiography, pulse wave velocity, and quality of life evaluations, at baseline and after 6 months of treatment. The study focuses on patients with CKD who are already on stable doses of ACE inhibitors or ARBs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent
* ≥ 18 years of age
* Chronic kidney disease (CKD), defined as evidence of decreased eGFR (eGFR ≥20 and \<60 mL/minute per 1.73 m2) or between eGFR ≥60 and \<90 mL/minute per 1.73 m2 with urinary albumin:creatinine ratio ≥200 mg/g or protein:creatinine ratio ≥300 mg/g
* Stable treatment with clinically appropriate doses of ACEi/ARB among CKD patients with proteinuria and uptitrated to maximal recommended or tolerated dose for at least 4 weeks before randomization, if not medically contraindicated
* For patients with type 2 diabetes:

Stable antihyperglycemic treatment \> 30 days before screening

* Female patients should either not be of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing one of the following methods of contraception throughout the study and for 30 days after study completion: Hormonal contraception (oral contraceptives, contraceptive implant, injectable birth control, contraceptive patch, or vaginal ring) or intrauterine device
* Ability to understand and read Danish

Exclusion Criteria:

* Type 1 diabetes
* For patients with type 2 diabetes:

History of diabetic ketoacidosis

* Patients undergoing dialysis
* History of organ transplant
* Treatment with SGLT2 inhibitor within 8 weeks prior to enrolment
* Known allergy or hypersensitivity to SGLT2 inhibitors or Placebo ingredients
* Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks of enrolment
* Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment
* Any condition outside the renal and cardiovascular study area with a life expectancy of \<2 years based on investigator's clinical judgement
* Hepatic impairment (aspartate transaminase or alanine transaminase \>3 times the upper limit of normal \[ULN\] or total bilirubin \>2 times the ULN at the time of enrolment)
* Known blood-borne diseases, such as Hepatitis A, B, C, D, and E, and Human immunodeficiency virus (HIV) types 1 and 2, Ebola, Lassa fever virus.
* Female patients who are pregnant, lactating, or are considering becoming pregnant during the study or for 6 months after study completion
* Participation in another clinical study with an investigational product within the last month prior to enrolment
* Inability to understand or comply with the investigational product, procedures, and/or follow-up or any conditions that may prevent the participant to complete the study

Where it's running

• Gentofte Hospital
  Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Katja Vu Bartholdy, MD
• Email: katja.vu.bartholdy@regionh.dk
• Phone: +4531360232

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Impact of TAVR on kidney function in people with aortic valve disease

  This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, RM · NCT07626710

• Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs

  This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.

  Recruiting Odense University Hospital · Odense · NCT07511283

• Oral Semaglutide for CKD and MAFLD in adults with diabetes

  This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT07391267

• Eye-brain-kidney connections in chronic kidney disease

  This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.

  Recruiting Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07358572

• Screening for chronic kidney disease

  We will see how common chronic kidney disease is among adults followed at a tertiary care center and how many cases were previously undiagnosed.

  Recruiting Institute for Clinical and Experimental Medicine · Prague · NCT07153432

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.